NEUK203-215 + fludarabine + cyclophosphamide

NEUK203-215 + fludarabine + cyclophosphamide is an investigational **combination therapy** studied for use in severe, refractory autoimmune diseases. NEUK203-215 is an allogeneic (healthy donor-derived) CAR-NK cell product engineered to target both CD19 and BCMA, antigens found on B cells and plasma cells. Fludarabine and cyclophosphamide are chemotherapeutic agents used as a lymphodepletion regimen before cell therapy infusion. The primary mechanism is immunotherapy via allogeneic CAR-NK cells, with the chemotherapeutic agents reducing host immune cells to enhance engraftment and efficacy of the NK cell product. The combination is being evaluated for its safety, tolerability, and preliminary efficacy[1][3].